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Immune responses contribute to the success of radiation
therapy of solid tumors; however, the mechanism of trig-
gering CD8+ T cell responses is poorly understood. Anti-
gen cross-presentation from tumor cells by dendritic cells
(DC) is a likely dominant mechanism to achieve CD8+ T
cell stimulation. We established a cross-presentation
model in prostate cancer in which DC present a naturally
expressed oncofoetal tumor antigen (5T4) from irradiated
DU145 tumor cells to 5T4-specific T cells. Ionising radia-
tion (12 Gy) caused G2/M cell cycle arrest and cell death,
increased cellular 5T4 levels, induced passive release of
high-mobility protein group-B1 (HMGB1) and upregu-
lated surface calreticulin and Hsp70 expression in DU145
cells. Co-culture of DC with irradiated tumor cells lead to
efficient phagocytosis of tumor cells and upregulation of
CD86 and HLA-DR on DC. CD8+ 5T4-specific T cells, sti-
mulated with these DC, proliferated and produced IFNg.
Inhibition of HMGB1 function decreased T cell stimula-
tion but not DC activation, while TRIF/MyD88 inhibition
only had a marginal effect on T cell stimulation. Unlike
previous reports, we found no functional evidence that DC
with Asp299Gly toll-like receptor-4 (TLR4) single nucleo-
tide polymorphism had impaired ability to cross-present
tumor antigen. However, we observed a highly significant
and robust prevention of antigen cross-presentation when
tumor cells were pre-treated with the novel Hsp70 inhibi-
tor, VER155008. The inhibitor also prevented CD86 upre-
gulation on DC co-cultured with irradiated tumor cells.
Together, our study demonstrates that radiation induces
immunologically relevant changes in tumor cells, which
can trigger CD8+ T cell responses via a predominantly
Hsp70-dependent antigen cross-presentation process.
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